workshop
canadian
societi
virolog
special
workshop
annual
meet
american
societi
virolog
held
june
beauti
virginia
tech
campu
blacksburg
virginia
workshop
provid
forum
discuss
recent
advanc
field
inform
set
conduc
interact
colleagu
featur
two
internationallyrenown
canadian
keynot
speaker
discuss
translat
virolog
research
american
societi
virolog
presid
grant
mcfadden
univers
florida
reloc
arizona
state
univers
present
studi
oncolyt
poxvirus
matthew
miller
mcmaster
univers
review
prospect
univers
influenza
vaccin
workshop
also
featur
varieti
traine
oral
poster
present
panel
discuss
topic
futur
csv
viru
research
canada
canadian
virologist
includ
worldrenown
expert
basic
clinic
epidemiolog
research
made
import
contribut
fundament
understand
mani
virus
led
develop
new
strategi
monitor
prevent
treat
viral
diseas
canada
meet
challeng
emerg
chronic
viral
infect
realiz
potenti
lead
research
area
virolog
research
commun
must
come
togeth
exchang
idea
discov
new
opportun
collabor
recogn
outstand
need
better
way
canadian
virolog
research
commun
interact
found
canadian
societi
virolog
csv
canadienn
pour
la
virologi
scv
figur
seek
creat
structur
foster
collabor
acceler
translat
virolog
research
find
posit
health
outcom
canadian
launch
csv
develop
special
workshop
conjunct
annual
meet
american
societi
virolog
workshop
first
scientif
activ
newlyfound
csv
object
workshop
canadian
societi
virolog
highlight
divers
excel
canadian
virolog
research
mobil
canadian
viru
research
across
differ
disciplin
basic
clinic
social
epidemiolog
creat
broader
base
research
expertis
commit
tackl
new
challeng
follow
introductori
comment
dr
nathali
grandvaux
de
centr
de
recherch
du
centr
hospitali
de
de
crchum
workshop
open
keynot
lectur
expatri
canadian
dr
grant
mcfadden
univers
florida
reloc
arizona
state
univers
role
american
societi
virolog
asv
presid
dr
mcfadden
welcom
attende
express
support
initi
well
known
lead
expert
rabbit
poxviru
known
myxoma
viru
mcfadden
elucid
mani
aspect
virushost
interact
link
key
poxviru
protein
immun
evas
pathogenesi
also
led
effort
test
oncolyt
properti
virus
widelyheld
view
defect
antivir
defens
achil
heel
cancer
cell
exploit
oncolyt
virotherapi
mcfadden
made
case
myxoma
viru
promis
oncolyt
agent
kill
varieti
human
cancer
cell
vitro
nonpathogen
outsid
rabbit
host
genet
tractabl
evid
preexist
antibodi
human
popul
recent
year
mcfadden
investig
potenti
myxoma
viru
ex
vivo
virotherapi
treat
residu
cancer
autolog
hematopoiet
stem
cell
transplant
repopul
hematopoiet
compart
follow
radiat
chemotherapi
risk
autolog
transplant
materi
could
harbor
cancer
cell
mcfadden
show
ex
vivo
myxoma
viru
therapi
delet
cancer
cell
transplant
without
harm
selfrenew
stem
cell
select
come
fact
myxoma
viru
bind
infect
normal
human
cell
also
show
ex
vivo
myxoma
viru
therapi
prevent
one
major
advers
outcom
allogen
hematopoiet
stem
cell
transplant
known
graft
vs
host
diseas
gvhd
caus
immunolog
attack
target
recipi
organ
donor
allogen
cell
mcfadden
close
lectur
tribut
renown
virologist
dr
john
colter
chair
depart
biochemistri
univers
alberta
hire
mcfadden
first
independ
posit
provid
import
earli
career
mentorship
first
traine
present
msc
student
alexa
robitail
de
crchum
present
studi
regul
antivir
signal
transduct
respons
paramyxoviru
infect
viral
nucleic
acid
recogn
sentinel
protein
cytoplasm
includ
retino
acid
induc
gene
rigi
melanoma
differentiationassoci
protein
activ
downstream
signal
transduct
pathway
lead
establish
antivir
state
activ
termin
antivir
signal
transduct
heavili
regul
posttransl
modif
notabl
phosphoryl
mani
activ
kinas
identifi
less
known
phosphatas
neg
regul
respons
limit
gener
inappropri
inflammatori
respons
notabl
phosphatas
yet
identifi
dephosphoryl
jun
ntermin
kinas
follow
introductori
comment
dr
nathali
grandvaux
de
centr
de
recherch
du
centr
hospitali
de
de
crchum
workshop
open
keynot
lectur
expatri
canadian
dr
grant
mcfadden
univers
florida
reloc
arizona
state
univers
role
american
societi
virolog
asv
presid
dr
mcfadden
welcom
attende
express
support
initi
well
known
lead
expert
rabbit
poxviru
known
myxoma
viru
mcfadden
elucid
mani
aspect
virushost
interact
link
key
poxviru
protein
immun
evas
pathogenesi
also
led
effort
test
oncolyt
properti
virus
widelyheld
view
defect
antivir
defens
achil
heel
cancer
cell
exploit
oncolyt
virotherapi
mcfadden
made
case
myxoma
viru
promis
oncolyt
agent
kill
varieti
human
cancer
cell
vitro
nonpathogen
outsid
rabbit
host
genet
tractabl
evid
preexist
antibodi
human
popul
recent
year
mcfadden
investig
potenti
myxoma
viru
ex
vivo
virotherapi
treat
residu
cancer
autolog
hematopoiet
stem
cell
transplant
repopul
hematopoiet
compart
follow
radiat
chemotherapi
risk
autolog
transplant
materi
could
harbor
cancer
cell
mcfadden
show
ex
vivo
myxoma
viru
therapi
delet
cancer
cell
transplant
without
harm
selfrenew
stem
cell
select
come
fact
myxoma
viru
bind
infect
normal
human
cell
also
show
ex
vivo
myxoma
viru
therapi
prevent
one
major
advers
outcom
allogen
hematopoiet
stem
cell
transplant
known
graft
vs
host
diseas
gvhd
caus
immunolog
attack
target
recipi
organ
donor
allogen
cell
mcfadden
close
lectur
tribut
renown
virologist
dr
john
colter
chair
depart
biochemistri
univers
alberta
hire
mcfadden
first
independ
posit
provid
import
earli
career
mentorship
first
traine
present
msc
student
alexa
robitail
de
crchum
present
studi
regul
antivir
signal
transduct
respons
paramyxoviru
infect
viral
nucleic
acid
recogn
sentinel
protein
cytoplasm
includ
retino
acid
induc
gene
rigi
melanoma
differentiationassoci
protein
activ
downstream
signal
transduct
pathway
lead
establish
antivir
state
activ
termin
antivir
signal
transduct
heavili
regul
posttransl
modif
notabl
phosphoryl
mani
activ
kinas
identifi
less
known
phosphatas
neg
regul
respons
limit
gener
inappropri
inflammatori
respons
notabl
phosphatas
yet
identifi
dephosphoryl
jun
ntermin
kinas
jnk
mitogenactiv
protein
kinas
mapk
enzym
follow
paramyxoviru
infect
ms
robitail
report
dual
specif
phosphatas
strongli
upregul
respons
infect
paramyxovirus
sendai
viru
sev
respiratori
syncyti
viru
rsv
ectop
overexpress
infect
diminish
level
phosphoryl
jnk
mapk
wherea
rna
interfer
opposit
effect
surprisingli
inhibit
mapk
phosphoryl
effect
downstream
phosphoryl
activ
transcript
factor
cjun
level
cytokin
elicit
infect
moreov
ectop
express
effect
rsv
replic
cell
cultur
ms
robitail
hypothes
system
may
affect
differ
pool
jnk
mapk
enzym
govern
altern
function
leav
activ
protein
mediat
cytokin
product
intact
hepat
c
viru
hcv
rna
translat
host
protein
synthesi
machineri
long
precursor
polyprotein
process
three
structur
seven
nonstructur
protein
govern
viral
replic
liverspecif
microrna
mirna
known
dictat
hcv
hepatotrop
bind
directli
hcv
rna
near
untransl
region
promot
hcv
rna
translat
replic
argonaut
ago
protein
compon
rnainduc
silenc
complex
risc
direct
activ
mirna
necessari
promot
hcv
replic
cycl
dr
joyc
wilson
univers
saskatchewan
step
present
research
postdoctor
fellow
dr
yalena
amadorcanizar
unabl
present
due
travel
delay
dr
wilson
report
use
genom
edit
technolog
knock
ago
protein
slice
rna
cleav
activ
knockout
cell
support
hcv
replic
suggest
least
one
ago
protein
sustain
high
level
hcv
replic
absenc
dr
wilson
indic
import
method
knock
combin
four
ago
protein
elucid
role
hcv
replic
camel
primari
amplifi
host
merscov
sourc
outbreak
human
popul
one
health
approach
propos
prevent
human
merscov
infect
vaccin
camel
camel
model
demonstr
effici
merscov
replic
upper
respiratori
tract
shed
viru
sever
factor
includ
high
cost
obtain
hous
camel
limit
util
model
merscov
vaccin
develop
dr
darryl
falzarano
vaccin
infecti
diseas
organizationintern
vaccin
centr
vidointervac
present
lowercost
altern
model
alpaca
new
world
camelid
previou
work
demonstr
seroposit
merscov
alpaca
furthermor
dipeptidyl
peptidas
cell
surfac
receptor
merscov
highli
conserv
alpaca
camel
alpaca
kidney
epitheli
cell
infect
ex
vivo
dr
falzarano
report
merscov
replic
high
titer
alpaca
intranasallyandor
intratracheallyinfect
merscov
irrespect
rout
administr
anim
merscov
rna
infecti
viru
nasal
swab
seroconvert
follow
infect
sign
clinic
diseas
final
dr
falzarano
demonstr
initi
infect
combin
rout
offer
protect
subsequ
infect
measur
viral
rna
level
recov
nasal
swab
suggest
alpaca
suitabl
altern
model
assess
vaccin
efficaci
prevent
viru
shed
rna
viru
replic
gener
complex
swarm
thousand
genet
variant
unknown
larg
unpredict
properti
high
mutat
rate
major
driver
rna
viru
evolut
rapid
emerg
adapt
mutat
affect
tropism
virul
fit
drug
resist
expatri
canadian
dr
marco
vignuzzi
pasteur
institut
present
approach
combin
experiment
evolut
mathemat
model
determin
evolutionari
trajectori
rna
viru
mutant
deep
sequenc
data
combin
bioinformat
permit
represent
mutat
space
fit
repres
third
dimens
use
approach
dr
vignuzzi
demonstr
viru
sequenc
space
predetermin
evolutionari
trajectori
alter
space
use
attenu
virus
vaccin
develop
approxim
individu
acut
hcv
infect
clear
viru
spontan
immunolog
basi
protect
chronic
hcv
infect
reinfect
common
amongst
intraven
drug
user
remain
elus
inde
individu
fail
clear
subsequ
infect
despit
preexist
hcvspecif
memori
lymphocyt
graduat
student
crchum
mentorship
dr
naglaa
shoukri
dr
moham
abdelhakeem
demonstr
viral
persist
upon
hcv
reinfect
associ
limit
expans
virusspecif
cell
wherea
protect
correl
expans
broad
set
hcvspecif
lymphocyt
conduct
longitudin
cell
receptor
analysi
creat
character
cell
clone
sort
cell
dr
abdelhakeem
discov
protect
immun
upon
hcv
reinfect
associ
focus
repertoir
hcvspecif
cell
recruit
memori
pool
wherebi
clonotyp
highest
function
avid
select
studi
implic
ration
design
hcv
vaccin
human
immunodefici
viru
type
prevent
effici
recognit
infect
cell
cytotox
lymphocyt
ctl
nef
protein
contribut
immun
evas
block
cell
surfac
local
major
histocompat
complex
mhci
therebi
prevent
present
viral
antigen
molecular
mechan
nefmedi
alter
protein
traffick
remain
incomplet
understood
use
bimolecular
fluoresc
complement
bifc
detect
interact
nef
mhci
brennan
dirk
western
univers
report
nefmhci
complex
local
earli
endosom
transgolgi
network
lysosom
compart
sitedirect
mutagenesi
reveal
residu
carboxytermin
tail
mhci
essenti
maintain
complex
format
nef
studi
reveal
nef
interact
cytosol
tail
mhci
divert
recycl
endosom
earli
endosom
highlight
import
earli
endocyt
network
remov
mhci
surfac
infect
cell
last
talk
morn
session
corina
warkentin
univers
ottawa
present
discoveri
small
molecul
block
entri
ebola
viru
ebov
human
cell
success
ebov
infect
requir
macropinocytosi
virion
cell
surfac
traffick
late
endosom
lysosom
compart
interact
receptor
known
niemannpick
protein
use
pseudotyp
murin
leukemia
virus
mlv
bear
ebov
glycoprotein
screen
small
molecul
could
select
block
infect
led
identif
sever
molecul
function
low
micromolar
rang
ms
warkentin
present
find
lead
molecul
compound
block
infect
nativ
ebov
well
varieti
mlv
pseudotyp
entri
glycoprotein
lassa
fever
viru
lymphocyt
choriomening
viru
junin
viru
sever
acut
respiratori
syndrom
coronaviru
sarscov
relat
filoviru
marburgviru
resist
compound
viru
attach
unperturb
suggest
compound
might
target
common
host
entri
factor
requir
postattach
step
follow
lunchtim
poster
session
dr
matthew
miller
mcmaster
univers
deliv
keynot
present
day
topic
broadlyneutr
antibodi
bnab
futur
prospect
univers
influenza
vaccin
dr
miller
describ
limit
current
multival
season
vaccin
monoval
pandem
vaccin
neglig
effect
spread
viru
due
rate
vaccin
product
distribut
factor
necessit
new
approach
vaccin
develop
discoveri
bnab
target
highlyconserv
stalk
domain
hemagglutinin
rais
hope
vaccin
capabl
confer
univers
immun
influenza
virus
antibodi
normal
made
low
quantiti
substanti
boost
exposur
pandemiclik
hemagglutinin
ha
protein
overcom
immunodomin
ha
head
domain
focus
research
effort
natur
polyclon
respons
dr
miller
discov
antibodi
isotyp
specif
major
consequ
bnab
function
specif
stalkbind
antibodi
iga
isotyp
greater
capac
neutral
viru
fcdepend
effector
function
bnab
regul
interact
among
multipl
antibodi
specif
find
like
profound
implic
success
gener
univers
influenza
viru
vaccin
therapeut
year
aleutian
mink
diseas
viru
amdv
sole
speci
genu
amdoparvoviru
recent
advanc
dna
sequenc
technolog
led
identif
four
novel
amdoparvovir
speci
ignit
new
studi
molecular
pathogenesi
epidemiolog
dr
marta
canuti
memori
univers
newfoundland
present
studi
amdv
molecular
epidemiolog
farm
wild
anim
newfoundland
contrast
data
worldwid
amdv
phylogeographi
evolut
amdv
highli
preval
newfoundland
farm
wild
mink
high
divers
within
singl
farm
high
coinfect
rate
farmspecif
recombin
polymorph
within
singl
infect
individu
final
predomin
neg
select
pressur
amdv
protein
observ
dr
canuti
document
movement
virus
farm
wild
also
exist
wildspecif
lineag
global
virus
differ
countri
fell
within
clade
form
countryspecif
subclad
studi
indic
high
amdv
preval
farm
facilit
coinfect
favor
viral
recombin
increas
viral
divers
amdv
move
farm
wild
exchang
differ
farm
countri
subsequ
evolut
parallel
lineag
gener
rapidli
evolv
virus
prophylact
vaccin
cover
seven
major
genotyp
gt
hcv
remain
elus
dr
jason
wong
univers
alberta
report
effort
develop
effect
hcv
vaccin
elicit
bnab
bind
conserv
region
hcv
envelop
glycoprotein
critic
viru
entri
known
vaccin
deriv
singl
strain
shown
elicit
bnab
guinea
pig
chimpanze
goat
healthi
human
volunt
epitop
map
studi
reveal
immun
goat
human
antisera
compet
bnab
bind
compet
especi
well
bnab
known
block
interact
major
cell
entri
receptor
inde
vaccin
directli
block
interact
collect
studi
suggest
immun
hcv
envelop
glycoprotein
elicit
nab
block
earli
stage
hcv
entri
result
support
use
vaccin
antigen
induc
crossgenotyp
neutral
workshop
close
group
discuss
led
dr
craig
mccormick
concern
csv
prioriti
futur
activ
consensu
csv
play
integr
role
develop
strong
multidisciplinari
commun
viru
research
canada
agreement
primari
focu
csv
organ
recurr
workshop
held
independ
conjunct
meet
opportun
aris
strong
support
idea
futur
csv
workshop
maintain
focu
traine
keep
cost
low
maxim
opportun
traine
attend
provid
ampl
opportun
oral
poster
present
provid
travel
award
select
peerreview
abstract
figur
urg
collabor
wellestablish
canadian
societi
microbiolog
csm
common
goal
discuss
strengthen
foundat
csv
left
commun
high
expect
upcom
csv
activ
follow
discuss
adjourn
group
join
colleagu
around
world
recept
open
keynot
lectur
virus
workshop
close
group
discuss
led
dr
craig
mccormick
concern
csv
prioriti
futur
activ
consensu
csv
play
integr
role
develop
strong
multidisciplinari
commun
viru
research
canada
agreement
primari
focu
csv
organ
recurr
workshop
held
independ
conjunct
meet
opportun
aris
strong
support
idea
futur
csv
workshop
maintain
focu
traine
keep
cost
low
maxim
opportun
traine
attend
provid
ampl
opportun
oral
poster
present
provid
travel
award
select
peerreview
abstract
figur
urg
collabor
wellestablish
canadian
societi
microbiolog
csm
common
goal
discuss
strengthen
foundat
csv
left
commun
high
expect
upcom
csv
activ
follow
discuss
adjourn
group
join
colleagu
around
world
recept
open
keynot
lectur
